Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9818873 | 0.78 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL9818904 | 0.74 | RAB9A (0.52) | PPARGPPARA | |
| SCHEMBL23258795 | 0.74 | TYR (0.44) | — | |
| SCHEMBL11292923 | 0.71 | PPARG (0.50) | PPARGPPARA | |
| SCHEMBL7324691 | 0.70 | NR4A1 (0.57) | PPARGPPARA | |
| SCHEMBL1847856 | 0.69 | ALDH1A1 (0.44) | PPARGPPARA | |
| SCHEMBL1547758 | 0.68 | LMNA (0.61) | PPARGPPARA | |
| SCHEMBL10983132 | 0.68 | CPA1 (0.53) | PPARGPPARA | |
| SCHEMBL1261707 | 0.68 | TRPA1 (0.50) | PPARGPPARA | |
| Hydrochloric Acid SCHEMBL10773246 | 0.68 | LMNA (0.47) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073131-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230406803-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Kinesid Therapeutics, Inc (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4045477-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076938-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406803-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | TXNRD2, TFRC, SDHB | PPARG 1248/4885PPARA 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.